Development and validation of the ID-EC - the ITALIAN version of the identify chronic migraine.


Journal

The journal of headache and pain
ISSN: 1129-2377
Titre abrégé: J Headache Pain
Pays: England
ID NLM: 100940562

Informations de publication

Date de publication:
13 Feb 2019
Historique:
received: 30 10 2018
accepted: 24 01 2019
entrez: 15 2 2019
pubmed: 15 2 2019
medline: 14 5 2019
Statut: epublish

Résumé

Case-finding tools, such as the Identify Chronic Migraine (ID-CM) questionnaire, can improve detection of CM and alleviate its significant societal burden. We aimed to develop and validate the Italian version of the ID-CM (ID-EC) in paper and as a smart app version in a headache clinic-based setting. The study investigators translated and adapted to the Italian language the original ID-CM questionnaire (ID-EC) and further implemented it as a smart app. The ID-EC was tested in its paper and electronic version in consecutive patients referring to 9 Italian tertiary headache centers for their first in-person visit. The scoring algorithm of the ID-EC paper version was applied by the study investigators (case-finding) and by patients (self-diagnosis), while the smart app provided to patients automatically the diagnosis. Diagnostic accuracy of the ID-EC was assessed by matching the questionnaire results with the interview-based diagnoses performed by the headache specialists during the visit according to the criteria of International Classification of Headache Disorders, III edition, beta version. We enrolled 531 patients in the test of the paper version of ID-EC and 427 in the validation study of the smart app. According to the clinical diagnosis 209 patients had CM in the paper version study and 202 had CM in the smart app study. 79.5% of patients returned valid paper questionnaires, while 100% of patients returned valid and complete smart app questionnaires. The paper questionnaire had a 81.5% sensitivity and a 81.1% specificity for case-finding and a 30.7% sensitivity and 90.7% specificity for self-diagnosis, while the smart app had a 64.9% sensitivity and 90.2% specificity. Our data suggest that the ID-EC, developed and validated in tertiary headache centers, is a valid case-finding tool for CM, with sensitivity and specificity values above 80% in paper form, while the ID-EC smart app is more useful to exclude CM diagnosis in case of a negative result. Further studies are warranted to assess the diagnostic accuracy of the ID-EC in general practice and population-based settings.

Sections du résumé

BACKGROUND BACKGROUND
Case-finding tools, such as the Identify Chronic Migraine (ID-CM) questionnaire, can improve detection of CM and alleviate its significant societal burden. We aimed to develop and validate the Italian version of the ID-CM (ID-EC) in paper and as a smart app version in a headache clinic-based setting.
METHODS METHODS
The study investigators translated and adapted to the Italian language the original ID-CM questionnaire (ID-EC) and further implemented it as a smart app. The ID-EC was tested in its paper and electronic version in consecutive patients referring to 9 Italian tertiary headache centers for their first in-person visit. The scoring algorithm of the ID-EC paper version was applied by the study investigators (case-finding) and by patients (self-diagnosis), while the smart app provided to patients automatically the diagnosis. Diagnostic accuracy of the ID-EC was assessed by matching the questionnaire results with the interview-based diagnoses performed by the headache specialists during the visit according to the criteria of International Classification of Headache Disorders, III edition, beta version.
RESULTS RESULTS
We enrolled 531 patients in the test of the paper version of ID-EC and 427 in the validation study of the smart app. According to the clinical diagnosis 209 patients had CM in the paper version study and 202 had CM in the smart app study. 79.5% of patients returned valid paper questionnaires, while 100% of patients returned valid and complete smart app questionnaires. The paper questionnaire had a 81.5% sensitivity and a 81.1% specificity for case-finding and a 30.7% sensitivity and 90.7% specificity for self-diagnosis, while the smart app had a 64.9% sensitivity and 90.2% specificity.
CONCLUSIONS CONCLUSIONS
Our data suggest that the ID-EC, developed and validated in tertiary headache centers, is a valid case-finding tool for CM, with sensitivity and specificity values above 80% in paper form, while the ID-EC smart app is more useful to exclude CM diagnosis in case of a negative result. Further studies are warranted to assess the diagnostic accuracy of the ID-EC in general practice and population-based settings.

Identifiants

pubmed: 30760199
doi: 10.1186/s10194-019-0966-3
pii: 10.1186/s10194-019-0966-3
pmc: PMC6734365
doi:

Types de publication

Journal Article Validation Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

15

Subventions

Organisme : Fondazione Italiana per lo Studio delle Cefalee (FISC)
ID : NA

Références

Headache. 1998 Jul-Aug;38(7):497-506
pubmed: 15613165
Headache. 2009 Apr;49(4):498-508
pubmed: 19245386
Cephalalgia. 2015 Jun;35(7):563-78
pubmed: 25304766
Cephalalgia. 2009 Dec;29(12):1285-93
pubmed: 19438916
Cephalalgia. 2016 Mar;36(3):203-15
pubmed: 26002700
Cephalalgia. 2010 May;30(5):599-609
pubmed: 19614702
Lancet Neurol. 2004 Aug;3(8):475-83
pubmed: 15261608
Cephalalgia. 2013 Aug;33(11):885-90
pubmed: 23482725
Acad Emerg Med. 1996 Sep;3(9):895-900
pubmed: 8870764
J Headache Pain. 2012 Jul;13(5):361-78
pubmed: 22644214
Headache. 2013 Jan;53(1):81-92
pubmed: 23078241
Neurology. 2008 Aug 19;71(8):559-66
pubmed: 18711108
Cephalalgia. 2013 Jul;33(9):629-808
pubmed: 23771276
Headache. 2011 Jul-Aug;51(7):1058-77
pubmed: 21762134
Cephalalgia. 2011 Feb;31(3):301-15
pubmed: 20813784
J Occup Environ Med. 2010 Jan;52(1):8-14
pubmed: 20042889

Auteurs

Simona Sacco (S)

Department of Applied Clinical Sciences and Biotechnology, Section of Neurology, University of L'Aquila, L'Aquila, Italy. simona.sacco@univaq.it.

Silvia Benemei (S)

Department of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Florence, Florence, Italy.

Sabina Cevoli (S)

IRCCS Institute of Neurological Science of Bologna, Bologna, Italy.

Gianluca Coppola (G)

Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University Polo Pontino, Latina, Italy.

Pietro Cortelli (P)

IRCCS Institute of Neurological Science of Bologna, Bologna, Italy.
Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.

Francesco De Cesaris (F)

Department of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Florence, Florence, Italy.

Roberto De Icco (R)

Headache Science Center, IRCCS C. Mondino Foundation, Pavia, Italy.

Cristiano Maria De Marco (CM)

Department of Clinical and Molecular Medicine, Regional Referral Headache Centre, Sant'Andrea Hospital, Sapienza University, Rome, Italy.

Cherubino Di Lorenzo (C)

Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University Polo Pontino, Latina, Italy.

Pierangelo Geppetti (P)

Department of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Florence, Florence, Italy.

Alessia Manni (A)

Department of Basic Medical Sciences, Neurosciences and Sense Organs, University of Bari, Bari, Italy.

Andrea Negro (A)

Department of Clinical and Molecular Medicine, Regional Referral Headache Centre, Sant'Andrea Hospital, Sapienza University, Rome, Italy.

Raffaele Ornello (R)

Department of Applied Clinical Sciences and Biotechnology, Section of Neurology, University of L'Aquila, L'Aquila, Italy.

Giulia Pierangeli (G)

IRCCS Institute of Neurological Science of Bologna, Bologna, Italy.
Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.

Francesco Pierelli (F)

IRCCS NEUROMED, Pozzilli, IS, Italy.

Lanfranco Pellesi (L)

Headache and Drug Abuse Research Centre, Policlinico Hospital, University of Modena e Reggio Emilia, Modena, Italy.

Luigi Alberto Pini (LA)

Headache and Drug Abuse Research Centre, Policlinico Hospital, University of Modena e Reggio Emilia, Modena, Italy.

Francesca Pistoia (F)

Department of Applied Clinical Sciences and Biotechnology, Section of Neurology, University of L'Aquila, L'Aquila, Italy.

Maria Pia Prudenzano (MP)

Department of Basic Medical Sciences, Neurosciences and Sense Organs, University of Bari, Bari, Italy.

Antonio Russo (A)

Headache Center, Department of Medical, Surgical, Neurological, Metabolic and Aging Sciences, University of Campania "Luigi Vanvitelli", Caserta, Italy.

Grazia Sances (G)

Headache Science Center, IRCCS C. Mondino Foundation, Pavia, Italy.

Valentina Taranta (V)

Department of Applied Clinical Sciences and Biotechnology, Section of Neurology, University of L'Aquila, L'Aquila, Italy.

Cristina Tassorelli (C)

Headache Science Center, IRCCS C. Mondino Foundation, Pavia, Italy.
Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy.

Gioacchino Tedeschi (G)

Headache Center, Department of Medical, Surgical, Neurological, Metabolic and Aging Sciences, University of Campania "Luigi Vanvitelli", Caserta, Italy.

Maria Trojano (M)

Department of Basic Medical Sciences, Neurosciences and Sense Organs, University of Bari, Bari, Italy.

Paolo Martelletti (P)

Department of Clinical and Molecular Medicine, Regional Referral Headache Centre, Sant'Andrea Hospital, Sapienza University, Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH